黄芪甲苷IV|cas:84687-43-4|西域试剂

黄芪甲苷IV,分析标准品,HPLC≥99.9%

产品编号：西域质检-TM24120| CAS NO：84687-43-4| 分子式：C₄₁H₆₈O₁₄| 分子量：784.970

Astragaloside IV 是从黄芪中分到的皂苷类物质，能够抑制 ERK1/2 和 JNK 的激活，在乳腺癌细胞 MDA-MB-231 中，能够下调 (MMP)-2，(MMP)-9 的信号通路。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
西域质检-TM24120		￥150.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

黄芪甲苷IV

Reference Material

This certificate is designed in accordance with ISO 17034 and ISO Guide 31. This reference material (RM) was designed,produced and verified in accordance with ISO/IEC 17025, ISO 17034 and a registered quality management system ISO 9001.

Product Name(产品名称) Astragaloside IV(黄芪甲苷IV)

Product Code(产品编号) 709701

Lot Number(产品批号) 22110867

CAS No. 84687-43-4

Mol. Weight(分子量) 784.97

Mol. Formula(分子式) C₄₁H₆₈O₁₄

Melting Point(熔点) N/A

Expiry Date(失效日期) 2024-Nov-28

Boiling point(沸点) N/A

Appearance(外观) White to Off-White Solid
(白色固体)______

Storage Temp(存储条件) (-18±5)℃,Keep in the shade
冷冻(-18±5)℃,置于阴凉处

C E R T I F I E D

Purity

99.9%

C E R T I F I E D

Expanded Uncertainty (U)

0.8%

Uncertainty

The certified value(s) and uncertainty(ies) are determined in accordance with ISO 17034 with an 95% confidence level(k=2). Uncertainty is based on the Total Combined Uncertainty, including uncertainties of characterisation, homogeneity and stability testing. Stability values are based on real evidence opposed to simulation.

Traceability

The balances used for gravimetric measurements are calibrated with weights traceable to the national standards. The calibration of the balances is verified annually by an external accredited calibration service. This analysis method has been verified using an approach consistent with ISO 17034:2016 & ISO 17025:2017.

CERTIFICATE ON	QC SIGNATURE
2022-Nov-29		RM Release

Method of Identification

HPLC

Method of Identification

HPLC

Intended Use

This RM is intended for use in a laboratory as a calibration and quality control standard or in method development for analytical techniques.

Storage

This reference material meets the specification stated in this certificate until the expiry date, provided it is stored unopened at the recommended temperature here in. If storage after opening is necessary, the RM should be tightly closed and kept from light and moisture.

Hazards

Read Material Safety Data Sheet (MSDS) and understand any potential hazard(s) prior to the use of this product. All chemicals should be considered potentially hazardous in nature and should only be handled by qualified personnel using established good laboratory practices.

Homogeneity

Random replicate samples of the final packaged RM have been analysed to prove homogeneity compliant with ISO 17034.

Instructions for use

It is recommended to use 1 mg as the minimum sample size and if less material is used, to increase the certified uncertainty by a factor of two for half sample and four for a quarter of sample.Visit the support section of our website technology videos and frequently asked questions.

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

个人防护装备	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
安全声明 (欧洲)	S22-S24/25
危险品运输编码	NONH for all modes of transport
海关编码	2932999099

1. 物质的识别

产品名：	Astragaloside IV
CAS号：	84687-43-4
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Astragaloside IV
分子式：	C41H68O14
分子量：	784.97

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

14. 其他信息

76. [6.656] Chuanjing Cheng et al."Astragaloside IV targets PRDX6, inhibits the activation of RAC subunit in NADPH oxidase 2 for oxidative damage."PHYTOMEDICINE.2023 Mar;:154795

75. [3.195] Yan, Fanchen et al."Glycoside combinations of Buyang Huanwu decoction ameliorate atherosclerosis via STAT3, HIF-1, and VEGF."NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY.2023 Jan;:1-17

74. [5.195] Zhen Xue et al."Untargeted metabolomics reveals the combination effects and mechanisms of Huangqi-fuzi herb-pair against doxorubicin-induced cardiotoxicity."JOURNAL OF ETHNOPHARMACOLOGY.2023 Apr;305:116109

73. [6.449] Yanmei Li et al."Regional variations and plant compartments shape the community structures of the endophytic microbiome and secondary metabolites of Astragalus mongholicus."INDUSTRIAL CROPS AND PRODUCTS.2023 Feb;192:116037

72. [IF=1.698] Jinyan Wu et al."Chemical Identification and Antioxidant Screening of Bufei Yishen Formula using an Offline DPPH Ultrahigh-Performance Liquid Chromatography Q-Extractive Orbitrap MS/MS."International Journal of Analytical Chemistry.2022 Oct 15;2022:142380

71. [IF=5.168] Pan Wang et al."Discovery and characterization of novel ATP citrate lyase inhibitors from natural products by a luminescence-based assay."CHEMICO-BIOLOGICAL INTERACTIONS.2022 Nov;367:110199

70. [IF=3.887] Xiang-Lin KONG et al."Effect of astragaloside IV and salvianolic acid B on antioxidant stress and vascular endothelial protection in the treatment of atherosclerosis based on metabonomics."Chinese Journal of Natural Medicines.2022 Aug;20:601

69. [IF=6.656] Xinying Fu et al."Glycosides from Buyang Huanwu Decoction inhibit atherosclerotic inflammation via JAK/STAT signaling pathway."PHYTOMEDICINE.2022 Oct;105:154385

68. [IF=4.769] Xinyi Chai et al."Screening of immune cell activators from Astragali Radix using a comprehensive two-dimensional NK-92MI cell membrane chromatography/C18 column/time-of-flight mass spectrometry system."Journal of Pharmaceutical Analysis. 2022 May;:

67. [IF=4.451] Liang Wang et al."Astragaloside IV protects diabetic cardiomyopathy against inflammation and apoptosis via regulating TLR4/MyD88/NF-κB signaling pathway."J Funct Foods. 2022 Jan;88:104905

66. [IF=3.168] Yuqiong Lin et al."Astragaloside IV Ameliorates Streptozotocin Induced Pancreatic β-Cell Apoptosis and Dysfunction Through SIRT1/P53 and Akt/GSK3β/Nrf2 Signaling Pathways."Diabet Metab Synd Ob. 2022 Jan;15:131-140

65. [IF=4.432] Hua Tian et al."Astragaloside IV protects against C/EBP homologous protein-mediated apoptosis in oxidized low-density lipoprotein-treated macrophages by promoting autophagy."Eur J Pharmacol. 2022 Mar;:174912

64. [IF=1.662] Hui Shi et al."Astragaloside IV prevents acute myocardial infarction by inhibiting the TLR4/MyD88/NF-κB signaling pathway."J Food Biochem. 2021 Jul;45(7):e13757

63. [IF=3] Qu Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950

62. [IF=3.098] Haifeng Jin et al."Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling."Int J Mol Med. 2021 Feb;47(2):595-606

61. [IF=3.434] Du Xiaoxun et al."Tanshinone IIA and Astragaloside IV Inhibit miR-223/JAK2/STAT1 Signalling Pathway to Alleviate Lipopolysaccharide-Induced Damage in Nucleus Pulposus Cells."Dis Markers. 2021;2021:6554480

60. [IF=3.69] Jingyi Hu et al."Qingchang Huashi Formula attenuates DSS-induced colitis in mice by restoring gut microbiota-metabolism homeostasis and goblet cell function."J Ethnopharmacol. 2021 Feb;266:113394

59. [IF=3.69] Xiaoping Wang et al."Baoyuan decoction ameliorates apoptosis via AT1-CARP signaling pathway in H9C2 cells and heart failure post-acute myocardial infarction rats."J Ethnopharmacol. 2020 Apr;252:112536

58. [IF=3.7] Jing-Jing Yang et al."Astragaloside IV enhances GATA-4 mediated myocardial protection effect in hypoxia/reoxygenation injured H9c2 cells."Nutr Metab Cardiovas. 2020 May;30:829

57. [IF=3.882] Kunpeng Yin et al."Lanthanide Metal–Organic Framework-Based Fluorescent Sensor Arrays to Discriminate and Quantify Ingredients of Natural Medicine."Langmuir. 2021;37(17):5321–5328

56. [IF=3.935] Yu-li Jiang et al."HPLC fingerprinting-based multivariate analysis of chemical components in Tetrastigma Hemsleyanum Diels et Gilg: Correlation to their antioxidant and neuraminidase inhibition activities."J Pharmaceut Biomed. 2021 Oct;205:114314

55. [IF=4.225] Zhang Wei et al."Five Active Components Compatibility of Astragali Radix and Angelicae Sinensis Radix Protect Hematopoietic Function Against Cyclophosphamide-Induced Injury in Mice and t-BHP–Induced Injury in HSCs."Front Pharmacol. 2019 Aug;0:936

54. [IF=4.36] Pin Gong et al."Hypoglycemic effect of astragaloside IV via modulating gut microbiota and regulating AMPK/SIRT1 and PI3K/AKT pathway."J Ethnopharmacol. 2021 Dec;281:114558

53. [IF=6.081] Tongji Liu et al."Improvement Effect of Lotus Leaf Flavonoids on Carbon Tetrachloride-Induced Liver Injury in Mice."Biomedicines. 2020 Feb;8(2):41

52. [IF=1.146] Han Gao et al."Proliferation and committed differentiation into dopamine neurons of neural stem cells induced by the active ingredients of radix astragali."Neuroreport. 2018 May 2; 29(7): 577–582

51. [IF=3.098] Xiao Chen et al."Astragaloside IV ameliorates high glucose‑induced renal tubular epithelial‑mesenchymal transition by blocking mTORC1/p70S6K signaling in HK‑2 cells."Int J Mol Med. 2019 Feb;43(2):709-716

50. [IF=4.213] Qiangyuan Fan et al."Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: Preparation by supercritical fluid technology and evaluation in vitro and in vivo."Int J Pharmaceut. 2018 Dec;552:360

49. [IF=4.354] Ting Liu et al."Synthetic Access Toward Cycloastragenol Glycosides."J Org Chem. 2017;82(8):4170–4178

48. [IF=4.759] Yuping Zhang et al."On-line surface plasmon resonance-high performance liquid chromatography–tandem mass spectrometry for analysis of human serum albumin binders from Radix Astragali."J Chromatogr A. 2013 Jun;1293:92

47. [IF=7.514] Yuping Zhang et al."Integration of magnetic solid phase fishing and off-line two-dimensional high-performance liquid chromatography–diode array detector–mass spectrometry for screening and identification of human serum albumin binders from Radix Astragali

46. Yang, Jing-Jing, et al. "Astragaloside IV enhances GATA-4 mediated myocardial protection effect in hypoxia/reoxygenation injured H9c2 cells." Nutrition, Metabolism and Cardiovascular Diseases 30.5 (2020): 829-842.https://doi.org/10.1016/j.numecd.2020.01.00

45. Fan, Qiangyuan, et al. "Improved oral bioavailability of notoginsenoside R1 with sodium glycocholate-mediated liposomes: preparation by supercritical fluid technology and evaluation in vitro and in vivo." International journal of pharmaceutics 552.1-2 (201

44. Ting Liu, Jin-Xi Liao, Yang Hu, Yuan-Hong Tu, and Jian-Song Sun The Journal of Organic Chemistry 2017 82 (8), 4170-4178 DOI: 10.1021/acs.joc.7b00080

43. Liu, Tongji, et al. "Improvement effect of lotus leaf flavonoids on carbon tetrachloride-induced liver injury in mice." Biomedicines 8.2 (2020): 41.https://doi.org/10.3390/biomedicines8020041

42. Wang, Xiaoping, et al. "Baoyuan decoction ameliorates apoptosis via AT1-CARP signaling pathway in H9C2 cells and heart failure post-acute myocardial infarction rats." Journal of ethnopharmacology 252 (2020): 112536.https://doi.org/10.1016/j.jep.2019.112536

41. 范小龙,陈冉,吴婉琴,刘国姣,黄坤,江丰.液相色谱串联质谱法测定食品中淫羊藿苷等20种功能成分[J].食品与机械,2021,37(01):86-93+98.

40. 田文仓. 不同生长年限及采收期子洲黄芪鉴别特征及其质量、产量差异分析[D].北京中医药大学,2020.

39. 徐芳芳,张秀莉,侯滔,曲腊腊,王纪霞,刘艳芳,梁鑫淼.天然产物中FFA1受体新激动剂的发现与研究[J].上海中医药大学学报,2021,35(01):12-19. [4]宫梦琪,孙倩,李振.天麻中天麻素提取工艺优化及抑制α-葡萄糖苷酶活性研究[J].中国果菜,2020,40(09):14-17+23.

38. 彭胜男,陶琰心,洪婷,杨海燕,黄青.黄芪甲苷通过mTORC1通路调控IgA肾病大鼠脾淋巴细胞分化[J].中国免疫学杂志,2021,37(04):421-425.

37. 张悦,于学炜,于宏川,仲伟一,杨阳.黄芪甲苷调节miR-21基因抑制肾癌细胞增殖和诱导细胞凋亡的机制探讨[J].现代肿瘤医学,2020,28(18):3145-3150.

36. 曾广伟,安慧仙,方东,高钊,贾建军,朱舜明.黄芪甲苷抑制缺血再灌注诱导的大鼠心肌细胞凋亡[J].现代生物医学进展,2020,20(24):4612-4617.

35. 彭胜男,陶琰心,洪婷,杨海燕,黄青.黄芪甲苷通过mTORC1通路调控IgA肾病大鼠脾淋巴细胞分化[J].中国免疫学杂志,2021,37(04):421-425.

34. 冯美杰,李蕾,王颖航,徐兢鸿,潘志.黄芪甲苷对人类风湿关节炎成纤维样滑膜细胞增殖及白细胞介素6分泌的影响[J].中国中医基础医学杂志,2020,26(10):1484-1487.

33. 程欢,米雅慧,刘明平,于洋,黎同明.黄芪多糖、黄芪甲苷对大黄酸肠吸收的影响[J].中药新药与临床药理,2021,32(02):240-244.

32. 姚萱航,刘翠晶,常晶茹,张雪薇,刘霞.2种类型膜荚黄芪主要药效成分含量及关键酶基因表达量差异研究[J].中草药,2021,52(07):2072-2081.

31. 冯紫薇. 子洲黄芪饮片质量等级标准研究[D].北京中医药大学,2020.

30. 赵宏月,张东伟,庞琳琳,张欢,于睿.黄芪甲苷及人参皂苷Rg1对高脂大鼠心肌缺血再灌注损伤后心肌细胞凋亡的影响[J].辽宁中医杂志,2021,48(02):188-191.

29. 孙乐,吴鹏,王春艳,张学兰,金玉翠,刘海滨.黄芪饮片炮制工艺优选[J].时珍国医国药,2020,31(07):1616-1619.

28. 张素清,陈冰,陈思邈,董静怡,陈伟燕,张宇燕.R语言与正交试验分析处理优化黄芪中黄芪甲苷提取工艺的比较[J].中国中医急症,2020,29(08):1420-1423.

27. 支旭然刘洪涛吴茵等. UPLC-MS/MS法同时测定肾康注射液中7个有效成分[J]. 药物分析杂志 2017 037(001):37-42.

26. 燕玉奎, 郭玫, 邵晶,等. 红芪及其不同提取部位中主要活性成分的含量测定[J]. 中兽医医药杂志, 2020, v.39;No.220(01):22-25.

25. 张婕,梁程程,杨爱仲,齐聪.增免抑瘤方及有效组分对卵巢癌干细胞裸鼠移植瘤Notch/Jagged1信号通路的影响[J].中国实验方剂学杂志,2020,26(15):46-53.

24. 邹龙, 李欢欢, 刘辉,等. 补阳还五汤总苷胶囊的制备工艺优选. 中国实验方剂学杂志.

23. 邹龙刘辉李仲秋等. HPLC测定补阳还五汤总苷中黄芪甲苷和芍药苷的含量[J]. 湖南中医药大学学报 2012 32(005):39-42.

22. 李富欣, 于蓓蓓, 刘瑾,等. 茯黄颗粒的质量标准研究[J]. 西部中医药, 2019, 032(002):P.44-48.

21. 何昊许畅王兴中苏力张家旭. 四种不同方法提取黄芪中黄芪甲苷的对比研究[J]. 化工科技(3期):25-28.

20. 韦赫, 程林, 吴培,等. 黄芪皂苷生物合成对短期水分变化的响应[J]. 中国中药杂志, 2019, 44(03):39-45.

19. 李杨, 郭超, 张小平,等. 黄芪皂苷-氢氧化铝佐剂复合物对bFGF肿瘤疫苗抗乳腺癌活性的影响[J]. 河西学院学报, 2018, 34(05):32-37.

18. 成鹏,白银亮,胡彩莉,连佛彦,周海宇.黄芪甲苷通过调控FoxO3a/Wnt2/β-catenin通路抑制去卵巢大鼠骨质疏松的作用[J].中国实验方剂学杂志,2018,24(15):161-166.

17. 张悦,于学炜,于宏川,仲伟一,杨阳.黄芪甲苷调节miR-21基因抑制肾癌细胞增殖和诱导细胞凋亡的机制探讨[J].现代肿瘤医学,2020,28(18):3145-3150.

16. 张怡, 靳晓飞, 周晓红,等. 黄芪甲苷调控自噬抑制缺氧缺糖/复氧复糖HT22细胞凋亡[J]. 中国药理学通报, 2019, 035(004):519-524.

15. 俞曼殊, 史俊, 赵君谊,等. 黄芪甲苷调控Akt信号通路阻抑人腹膜间皮细胞间充质转化的实验研究[J]. 南京中医药大学学报, 2019, 35(01):53-57.

14. 刘晨旭,张玫,杨洋,魏鹏翔,魏群利.黄芪甲苷对高糖诱导下大鼠肾小球系膜细胞TGF-β1/Smad信号通路的影响[J].徐州医科大学学报,2019,39(09):641-643.

13. 贾力维, 沃晓嫚, 王谦博,等. 黄芪甲苷对非小细胞肺癌A549细胞增殖及凋亡相关蛋白表达的影响[J]. 黑龙江大学自然科学学报, 2019, 036(001):84-89.

12. 熊莉,吕梦娟,窦德宇,马玉红.黄芪甲苷对血管紧张素Ⅱ诱导肾小球系膜细胞增殖及炎症因子表达的影响[J].中国应用生理学杂志,2018,34(05):414-417+421.

11. 赵彩萍,刘翠玲,梁爽,李欣蓉,柳雪蕾,朱美玲.黄芪甲苷对脂多糖诱导人胃黏膜上皮细胞GES-1的抗炎作用及机制研究[J].中药新药与临床药理,2020,31(08):918-923.

10. 张吉, 臧东钰. 黄芪甲苷对急性肺损伤大鼠内质网应激介导影响[J]. 中国民族民间医药, 2014, 000(015):19-20.

9. 武建毅, 沈清, 金赟洁,等. 黄芪甲苷对BALB/C小鼠肝癌H22腹水瘤抑制作用及机制[J]. 中国药物警戒, 2016, 13(003):138-142.

8. 朱易平, 李茹柳, 时玉霞,等. 黄芪总皂苷对IEC-6细胞增殖及相关蛋白表达的影响[J]. 中药新药与临床药理, 2019, 30(01):60-65.

7. 倪琳, 魏学冰, 陈德道,等. 黄芪乌梅降糖颗粒的制备工艺与质量分析[J]. 海峡药学, 2020, v.32;No.240(01):10-15.

6. 李玉美, 陈新梅, 徐溢明,等. 纳秒脉冲电场灭菌对舒心糖浆质量影响的初步研究[J]. 化工时刊, 2015(04):31-32+52.

5. 孟琦, 宝丽, 张烨,等. 基于肠道菌群调节的小檗碱和黄芪甲苷联用降糖机制研究[J]. 食品与药品, 2020(3):169-175.

4. 孙铭忆, 李冰韶, 王永洁,等. 基于模糊层次分析法优选复方黄芪水浸膏提取工艺路线[J]. 中草药, 2018.

3. 陈开, 周静, 李敏,等. 基于大孔树脂的黄芪中黄芪甲苷提取液纯化工艺研究[J]. 中国中医急症, 2017, 26(011):1881-1883.

2. 袁一凡陈晓月刘保霞刘笑李瑞宏祁金龙贾庆忠.UPLC-MS/MS法同时测定康艾注射液中11种成分[J].中草药 2017 48(13):2660-2665.

1. 张素清陈冰陈思邈等. R语言与正交试验分析处理优化黄芪中黄芪甲苷提取工艺的比较[J]. 中国中医急症 2020(8).